niftify.in

The Economic Times

Alkem joins $3 bn race for JB Chem as Torrent pauses talks

Alkem Laboratories, India's fifth-largest branded pharmaceutical company, is vying for JB Chemicals and Pharmaceuticals as KKR looks to sell. Torrent Pharmaceuticals has exited negotiations over valuation differences. If successful, this will be Alkem's largest acquisition, enhancing its presence in the chronic segment and potentially moving it to fourth place in the domestic formulations market.

The Economic Times

Alkem inks licensing pact with Takeda to introduce Vonoprazan in India

Alkem Laboratories has entered into a patent licensing agreement with Takeda Pharmaceutical to market Vonoprazan in India. This medication is used to treat conditions like reflux esophagitis and various ulcers. This licensing deal will enhance Alkem's offerings in the gastrointestinal segment, according to CEO Vikas Gupta. The company's shares dropped 1.66% on Monday.

The Economic Times

Persistent Systems, Alkem Laboratories among 6 midcap stocks hit all-time high on Thursday

Domestic equity benchmarks Sensex and Nifty hit record highs on Thursday, boosted by heavyweight conglomerate Reliance Industries, which plans to step up the adoption of AI and issue bonus shares.

The Economic Times

Alkem arm ties up with Exactech for knee, hip replacement implants

Alkem Laboratories has announced a partnership through its subsidiary, Alkem MedTech, with US-based Exactech Inc to manufacture and market large joint implants in India. The deal grants Alkem MedTech marketing rights for Exactech's implant brands, including Truliant, Optetrak, and Logic Fit.

Mint

Weekly picks: From TVS Motor to MCX - Motilal Oswal recommends three stocks to buy

Brokerage firm Motilal Oswal has listed three stocks - Alkem Laboratories, TVS Motor and MCX - to buy this week with decent upside move.

Mint

Torrent, Glenmark, Alkem, Mankind, Lupin among key drivers of Indian pharma market growth during July

Stock Market Today: Torrent Pharmaceuticals, Glenmark Pharmaceuticals, Mankind, Lupin, Alkem Laboratories were among key drivers of pharma market growth during July. Indian pharma market growth remained tepid at 6.1% suggest reports

Business Standard

Alkem Labs Q1 results: Net profit jumps 91% to Rs 550 cr on robust sales

Alkem Laboratories on Friday said its consolidated net profit increased by 91 per cent to Rs 550 crore in the first quarter ended June 2024, aided by robust sales. The drug firm had reported a net profit of Rs 288 crore in the April-June quarter of last fiscal. Total income increased to Rs 3,152 crore in the first quarter as against Rs 3,033 crore in the year-ago period, Alkem Laboratories said in a regulatory filing. "We are happy that our efforts to improve profitability have started paying off, and we have seen a marked increase in margins during the quarter," Alkem Laboratories CEO Vikas Gupta said. The company is committed to maximise EBITDA margin by managing product mix, controlling costs, and taking advantage of the favourable raw material pricing environment, he added. "The domestic business is our stronghold, and we expect to build on it by furthering the growth of our large brands and bridging portfolio gaps. Simultaneously, we are also focusing on growing our business